On the HCPLive Hepatitis C page, resources on the topics of medical news and expert insight into HCV can be found. Content includes articles, interviews, videos, podcasts, and breaking news on hepatitis C virus research, treatment, and drug development.
February 6th 2025
Findings suggest the value of genotyping and histological assessment for guiding HCC screening decisions in patients with chronic HBV.
Improving the Care Cascade: Early Intervention for Perinatal HCV, with Megan Rose Curtis, MD
March 15th 2024Curtis discusses findings from her recent health economic study about the cost-effectiveness of treating perinatal HCV earlier, a growing concern amid rising rates of HCV in reproductive-aged adults.
Crisis Point: Stigma Hinders Adoption of Hepatitis C-Positive Donor Kidneys
March 14th 2024To acknowledge World Kidney Day, our latest episode of Crisis Point focuses on the stigma surrounding the use of HCV-positive donor kidneys amid the ongoing organ shortage crisis, with the perspective of a pair of experts and an HCV donor kidney recipient.
Hepatology Month in Review: January 2024
February 3rd 2024The editorial team’s monthly recap of the top news in hepatology features research emphasizing women’s health in liver disease, a look at some less-recognized health benefits associated with achieving SVR, and promising approaches for preventing and treating hepatic conditions.
Pregnant Women in Rural Regions Face Greater HCV, Preterm Birth Burden
January 26th 2024Results showed a 12% incidence of HCV in pregnancy with a preterm birth rate nearly double the national average, although no statistically significant difference in preterm birth rates was observed between HCV-positive and HCV-negative patients.
Achieving SVR Reduces Risk of Cardiovascular Events in Patients with HCV
January 23rd 2024Results highlight the benefit of achieving sustained virological response with DAAs for decreasing patients’ risk of carotid atherosclerosis and peripheral artery disease, especially among those with severe fibrosis.
Hepatitis C Genotype, Cirrhosis, Gender May Impact Effectiveness of DAA Therapy
January 11th 2024Although the overall response rate among the cohort was 96.4%, this figure dropped as low as 66.7% when accounting for male gender, GT3 infection, cirrhosis, obesity, and non-response to previous therapy.
Hepatitis B Markers, Reactivation Do Not Impact Effectiveness of DAA Therapy for HCV
January 10th 2024Response to direct-acting antiviral therapy was similar between patients with and without HBV coinfection, with most patients completing the planned course of treatment and achieving SVR, even in the case of HBV reactivation.
Increases in HCV-Related Liver Cancer Incidence, Mortality Suggest Rising Global Health Burden
January 9th 2024Investigators examined data from the Global Burden of Disease, Injuries, and Risk Factors study 2019 to describe the global, regional, and national burden of liver cancer due to hepatitis C since 1990.